Compare Alcon AG (ALC) vs YieldMax AMZN Option Income Strategy ETF (AMZY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs YieldMax AMZN Option Income Strategy ETF — how do they compare? Alcon AG trades at $73.83 (market cap $36.44B), while YieldMax AMZN Option Income Strategy ETF trades at $11.29. The key difference: Alcon AG pays a 0.48% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Alcon AG is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ALC | AMZY | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.12 | $15.75 |
52-Week Low | $62.02 | $9.98 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
AMZY trades at $11.29, down 2.84% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides weekly dividend distributions, with recent payouts ranging from $0.06 to $0.14, supporting high yield but raising sustainability concerns. Key support is at $11, with resistance at $12, as the RSI indicates potential overbought conditions near-term.
The outlook for AMZY hinges on its ability to maintain high dividend yields without eroding net asset value. Risks include NAV erosion from its synthetic option strategy and underperformance versus Amazon stock. Analyst sentiment is cautious due to structural drawbacks, making it suitable only for income-focused investors aware of the trade-offs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →
